Description
Vogliboseisaninhibitorofα-glucosidasethatexhibitsanti-diabetic,anti-hyperglycemic,anti-hyperlipidemic,anti-melanogenic,andcardioprotectivebenefits.Inobesemice,vogliboseincreasesplasmalevelsofglucagon-likepeptide1(GLP-1),indirectlydecreasingactivityofDPP4.Additionally,voglibosedecreasesexpressionofintracellularadhesionmolecule1(ICAM-1)andexcretionofC-reactiveprotein(CRP),alsodecreasingoxidativestress.Inclinicalstudies,vogliboseimprovesbodymassindexandhemoglobinA(1c)valuesanddecreaseshyperlipidemiaandhyperglycemia.Inhibitionofα-glucosidasealsoblocksN-glycanmodificationoftyrosinase,decreasinglevelsoftyrosinaseandmelanin.Inseveralanimalmodelsofmyocardialischemia/reperfusion,vogliboseupregulatesphosphorylatedAktandphosphorylatedeNOSexpression,decreasingmyocardialinfarctionsize;thiscompoundmayalsoactivateGLP-1receptorsoropenmitochondrialK+(ATP)channels,
References
BinBH,SeoJ,YangSH,etal.Novelinhibitoryeffectoftheantidiabeticdrugvogliboseonmelanogenesis.ExpDermatol.2013Aug;22(8):541-6.PMID:23879813.
IwasaM,KobayashiH,YasudaS,etal.Antidiabeticdrugvogliboseisprotectiveagainstischemia-reperfusioninjurythroughglucagon-likepeptide1receptorsandthephosphoinositide3-kinase-Akt-endothelialnitricoxidesynthasepathwayinrabbits.JCardiovascPharmacol.2010Jun;55(6):625-34.Erratumin:JCardiovascPharmacol.2012Jul;60(1):108.PMID:20351564.
KawamoriR,TajimaN,IwamotoY,etal.Vogliboseforpreventionoftype2diabetesmellitus:arandomised,double-blindtrialinJapaneseindividualswithimpairedglucosetolerance.Lancet.2009May9;373(9675):1607-14.PMID:19395079.
MoritohY,TakeuchiK,HazamaM.ChronicadmiNISTrationofvoglibose,analpha-glucosidaseinhibitor,increasesactiveglucagon-likepeptide-1levelsbyincreasingitssecretionanddecreasingdipeptidylpeptidase-4activityinob/obmice.JPharmacolExpTher.2009May;329(2):669-76.PMID:19208898.
SatohN,ShimatsuA,YamadaK,etal.Analpha-glucosidaseinhibitor,voglibose,reducesoxidativestressMarkersandsolubleintercellularadhesionmolecule1inobesetype2diabeticpatients.Metabolism.2006Jun;55(6):786-93.PMID:16713439.
